Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

The use of novel B-cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B-cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia. Ibrutinib, the fir...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Haematologica (Roma) Ročník 102; číslo 10; s. 1629 - 1639
Hlavní autoři:	de Weerdt, Iris, Koopmans, Suzanne M., Kater, Arnon P., van Gelder, Michel
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Italy Ferrata Storti Foundation 01.10.2017
Témata:	Agammaglobulinaemia Tyrosine Kinase Antineoplastic Agents - adverse effects Disease Management Drug Interactions Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - therapy Humans Incidence Leukemia, Lymphocytic, Chronic, B-Cell - complications Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphoma, B-Cell - complications Lymphoma, B-Cell - drug therapy Protein Kinase Inhibitors - adverse effects Protein-Tyrosine Kinases - antagonists & inhibitors Purines - administration & dosage Purines - adverse effects Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrimidines - administration & dosage Pyrimidines - adverse effects Quinazolinones - administration & dosage Quinazolinones - adverse effects Review Severity of Illness Index
ISSN:	0390-6078, 1592-8721, 1592-8721
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!